IL226504B - Increasing drug bioavailability in naltrexone therapy - Google Patents

Increasing drug bioavailability in naltrexone therapy

Info

Publication number
IL226504B
IL226504B IL226504A IL22650413A IL226504B IL 226504 B IL226504 B IL 226504B IL 226504 A IL226504 A IL 226504A IL 22650413 A IL22650413 A IL 22650413A IL 226504 B IL226504 B IL 226504B
Authority
IL
Israel
Prior art keywords
naltrexone
bioavailability
drug
increasing
treatment
Prior art date
Application number
IL226504A
Other languages
English (en)
Hebrew (he)
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL226504(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of IL226504B publication Critical patent/IL226504B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
IL226504A 2010-12-03 2013-05-23 Increasing drug bioavailability in naltrexone therapy IL226504B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41939510P 2010-12-03 2010-12-03
PCT/US2011/063177 WO2012075459A1 (en) 2010-12-03 2011-12-02 Increasing drug bioavailability in naltrexone therapy

Publications (1)

Publication Number Publication Date
IL226504B true IL226504B (en) 2021-01-31

Family

ID=46172304

Family Applications (3)

Application Number Title Priority Date Filing Date
IL226504A IL226504B (en) 2010-12-03 2013-05-23 Increasing drug bioavailability in naltrexone therapy
IL270841A IL270841A (en) 2010-12-03 2019-11-21 Increasing the bioavailability of a drug in treatment with naltrexone
IL279626A IL279626A (en) 2010-12-03 2020-12-21 Increasing the bioavailability of a drug in treatment with naltrexone

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL270841A IL270841A (en) 2010-12-03 2019-11-21 Increasing the bioavailability of a drug in treatment with naltrexone
IL279626A IL279626A (en) 2010-12-03 2020-12-21 Increasing the bioavailability of a drug in treatment with naltrexone

Country Status (27)

Country Link
US (1) US20130245056A1 (enExample)
EP (4) EP4349369B1 (enExample)
JP (5) JP6008866B2 (enExample)
KR (5) KR102105857B1 (enExample)
CN (1) CN103313711A (enExample)
AR (2) AR093182A1 (enExample)
AU (2) AU2011336304B2 (enExample)
BR (1) BR112013013390A2 (enExample)
CA (2) CA2819262C (enExample)
CL (1) CL2013001564A1 (enExample)
CY (2) CY1118968T1 (enExample)
DK (3) DK3222280T3 (enExample)
ES (2) ES2625527T3 (enExample)
FI (1) FI3884947T3 (enExample)
HR (3) HRP20170734T1 (enExample)
HU (3) HUE034393T2 (enExample)
IL (3) IL226504B (enExample)
LT (3) LT3222280T (enExample)
MX (2) MX384662B (enExample)
PL (3) PL3884947T3 (enExample)
PT (3) PT3884947T (enExample)
RS (3) RS65198B1 (enExample)
RU (1) RU2640561C2 (enExample)
SI (3) SI3884947T1 (enExample)
SM (3) SMT202400038T1 (enExample)
TW (1) TWI618536B (enExample)
WO (1) WO2012075459A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05011557A (es) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
EP2135603B1 (en) 2005-11-22 2013-01-02 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
CA2785822C (en) 2010-01-11 2019-06-25 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
RS65198B1 (sr) * 2010-12-03 2024-03-29 Nalpropion Pharmaceuticals Llc Povećana biodostupnost leka u terapiji naltreksonom
KR20200035501A (ko) 2012-06-06 2020-04-03 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
EP3253379A4 (en) * 2015-02-07 2018-10-10 Intas Pharmaceuticals Limited Pharmaceutical composition for the treatment of obesity
CN111050801B (zh) * 2017-03-28 2023-03-28 Ldn制药有限公司 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂
EP3482751A1 (en) 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096201A1 (en) * 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
EP1772147A2 (en) * 2003-03-17 2007-04-11 Japan Tobacco, Inc. Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
EP1907005A1 (en) 2005-07-27 2008-04-09 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP2135603B1 (en) 2005-11-22 2013-01-02 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US20070179168A1 (en) 2005-11-28 2007-08-02 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2484346B1 (en) * 2006-06-19 2017-02-22 Alpharma Pharmaceuticals LLC Pharmaceutical compositions
KR101264789B1 (ko) 2006-06-30 2013-05-15 엘지디스플레이 주식회사 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법
US7915307B2 (en) * 2006-07-20 2011-03-29 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US8088786B2 (en) * 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
JP2010508997A (ja) 2006-11-09 2010-03-25 オレキシジェン・セラピューティクス・インコーポレーテッド 減量薬を投与するための方法
RU2486899C2 (ru) * 2007-04-11 2013-07-10 Байомарин Фармасьютикал Инк. Композиции тетрагидробиоптерина и способы его количественной оценки
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
WO2009035473A2 (en) * 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
RS65198B1 (sr) 2010-12-03 2024-03-29 Nalpropion Pharmaceuticals Llc Povećana biodostupnost leka u terapiji naltreksonom

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096201A1 (en) * 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GREENWAY FL. ET. AL., GREENWAY FL. ET. AL., LANCET. 2010 AUG 21;376(9741):595-605., 21 August 2010 (2010-08-21) *

Also Published As

Publication number Publication date
CL2013001564A1 (es) 2014-05-02
KR20200044158A (ko) 2020-04-28
HRP20240115T1 (hr) 2024-06-07
EP2646031A1 (en) 2013-10-09
MX2013006071A (es) 2013-10-01
AU2011336304B2 (en) 2017-03-30
EP4349369A2 (en) 2024-04-10
EP3222280A1 (en) 2017-09-27
CA2819262C (en) 2024-05-28
JP2016210809A (ja) 2016-12-15
FI3884947T3 (fi) 2024-01-30
RU2640561C2 (ru) 2018-01-09
ES2625527T9 (es) 2018-09-25
CY1118968T1 (el) 2018-01-10
JP6456890B2 (ja) 2019-01-23
EP3884947A1 (en) 2021-09-29
PT3222280T (pt) 2021-04-22
IL270841A (en) 2020-01-30
HUE065852T2 (hu) 2024-06-28
PT2646031T (pt) 2017-05-25
EP3222280B1 (en) 2021-01-20
SI3222280T1 (sl) 2021-11-30
CA3239386A1 (en) 2012-06-07
SI2646031T1 (sl) 2017-07-31
WO2012075459A1 (en) 2012-06-07
SMT201700232T1 (it) 2017-07-18
CN103313711A (zh) 2013-09-18
EP4349369A3 (en) 2024-05-15
PL3884947T3 (pl) 2024-05-06
PL2646031T3 (pl) 2017-08-31
RS56014B1 (sr) 2017-09-29
ES2866879T3 (es) 2021-10-20
TWI618536B (zh) 2018-03-21
HUE034393T2 (en) 2018-02-28
HUE053831T2 (hu) 2021-07-28
KR102105857B1 (ko) 2020-05-04
PL3222280T3 (pl) 2021-11-29
MX356801B (es) 2018-06-13
SMT202100227T1 (it) 2021-07-12
IL279626A (en) 2021-03-01
DK2646031T3 (en) 2017-05-22
KR20140035320A (ko) 2014-03-21
EP2646031A4 (en) 2014-04-23
CY1124331T1 (el) 2022-07-22
HRP20210618T1 (hr) 2021-09-17
JP6008866B2 (ja) 2016-10-19
JP2022060331A (ja) 2022-04-14
KR20210063473A (ko) 2021-06-01
EP2646031B9 (en) 2018-01-10
RU2017144631A3 (enExample) 2021-04-13
HRP20170734T1 (hr) 2017-08-11
DK3222280T3 (da) 2021-04-19
PT3884947T (pt) 2024-02-16
AR093182A1 (es) 2015-05-27
TW201304780A (zh) 2013-02-01
RS62149B1 (sr) 2021-08-31
RS65198B1 (sr) 2024-03-29
LT2646031T (lt) 2017-06-26
US20130245056A1 (en) 2013-09-19
SMT202400038T1 (it) 2024-03-13
BR112013013390A2 (pt) 2016-09-06
CA2819262A1 (en) 2012-06-07
RU2013127423A (ru) 2015-01-10
EP4349369B1 (en) 2025-09-17
JP2013544290A (ja) 2013-12-12
EP3884947B1 (en) 2023-11-15
KR101984500B1 (ko) 2019-05-31
KR20190058702A (ko) 2019-05-29
LT3222280T (lt) 2021-05-10
RU2017144631A (ru) 2019-02-18
KR20180069089A (ko) 2018-06-22
JP2024071605A (ja) 2024-05-24
LT3884947T (lt) 2024-03-12
JP2019056004A (ja) 2019-04-11
AR124500A2 (es) 2023-04-05
JP7025319B2 (ja) 2022-02-24
SI3884947T1 (sl) 2024-06-28
DK3884947T3 (da) 2024-01-22
EP2646031B1 (en) 2017-02-22
ES2625527T3 (es) 2017-07-19
AU2017204309A1 (en) 2017-07-13
AU2011336304A1 (en) 2013-07-11
MX384662B (es) 2025-03-14
KR102258043B1 (ko) 2021-05-28
KR102391511B1 (ko) 2022-04-26

Similar Documents

Publication Publication Date Title
NO2023040I1 (no) Atogepant or a pharmaceutically acceptable salt thereof
CY2018029I1 (el) Αντι-ιικη θεραπεια
IL226504B (en) Increasing drug bioavailability in naltrexone therapy
IL226245A0 (en) History
IL245328A0 (en) Pharmaceutical composition
EP2748685A4 (en) PORTABLE MEDICINAL DISPENSER
EP2753233A4 (en) MEDICAL DEVICES WITH PROXIMITY DETECTION
HUE037108T2 (hu) Adagkapszula azonosítóval
ATE526024T1 (de) Fluvoxamin vermeidende pirfenidontheraphy
DK2652652T3 (da) Medikmentadministration
SI2582366T1 (sl) Farmacevtska kombinacija za zdravljenje bolečine
FI20105639A7 (fi) Mikroselluloosan valmistus
DK2437736T3 (da) Lægemiddelindgivelsessystemer
GB201017597D0 (en) Drug detection
BR112013008074A2 (pt) combinações farmacêuticas
EP2883547A4 (en) MEDICINE
HUE049344T2 (hu) Gyermekgyógyászati készítmény
BR112013000298A2 (pt) tablete
EP2564818A4 (en) MEDICAL STENT
DK2555819T3 (da) Lægemiddelafgivelsesindretning
ES1075346Y (es) Cateter integrado anti-retorno
FI20100366A0 (fi) Järjestelmä lääkityksen noudattamiseksi
IT1401468B1 (it) Contenitore per farmaci
FR2990112B1 (fr) Support d'assise
DK2670458T3 (da) Lægemiddelindgivelsesanordning

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed